What are the indications for Premarin (conjugated equine estrogens)?

Premarin Indications

Premarin (conjugated equine estrogens) is FDA-approved for treating moderate to severe vasomotor symptoms of menopause, moderate to severe vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism/castration/primary ovarian failure, palliation of metastatic breast cancer and advanced androgen-dependent prostate cancer, and prevention of postmenopausal osteoporosis (when non-estrogen medications are inappropriate). 1

FDA-Approved Indications

The official FDA labeling for Premarin specifies the following uses 1:

Primary Indications:

• Moderate to severe vasomotor symptoms (hot flashes, night sweats) associated with menopause
• Moderate to severe vulvar and vaginal atrophy symptoms due to menopause
  • Important caveat: When prescribing solely for vulvar/vaginal atrophy, topical vaginal products should be considered first 2, 1

Endocrine Disorders:

• Hypoestrogenism due to:
  • Hypogonadism
  • Castration (surgical menopause)
  • Primary ovarian failure

Cancer Palliation:

• Metastatic breast cancer (palliation only) in appropriately selected women and men
• Advanced androgen-dependent prostate carcinoma (palliation only)

Bone Health:

• Prevention of postmenopausal osteoporosis
  • Critical restriction: Should only be considered for women at significant risk of osteoporosis for whom non-estrogen medications are not appropriate 3, 1
  • Estrogen was never specifically approved for treatment of osteoporosis, only prevention 3

Clinical Context from Guidelines

Vasomotor Symptoms

The 2011 AACE guidelines emphasize that estrogen-containing products are the most effective FDA-approved therapies for moderate to severe vasomotor symptoms 2. Hot flashes affect up to 70% of women undergoing natural menopause and nearly all women with surgical menopause 2.

Osteoporosis Prevention - Important Limitations

While conjugated equine estrogen (0.625 mg daily) was shown in the Women's Health Initiative to reduce fractures of the spine, hip, and nonvertebral sites 3, current recommendations emphasize:

• Use only when non-estrogen medications are not appropriate 3
• Consider weight-bearing exercise, adequate calcium (1500 mg/day) and vitamin D (400-800 IU/day) as mainstays 1
• Use the lowest dose for the shortest duration necessary 3

Dosing Considerations

The 2011 AACE guidelines specify common Premarin doses 2:

• 0.3 to 0.625 mg daily for conjugated equine or synthesized conjugated estrogens
• The dose should be the lowest amount necessary to provide symptom relief or bone protection, with consideration for reducing dose with advancing age 2

Critical Contraindications

Premarin should not be used in 1:

• Undiagnosed abnormal genital bleeding
• Known, suspected, or history of breast cancer (except for metastatic disease palliation)
• Known or suspected estrogen-dependent neoplasia
• Active or history of deep vein thrombosis or pulmonary embolism
• Active or recent (within past year) arterial thromboembolic disease (stroke, MI)
• Liver dysfunction or disease
• Known hypersensitivity to ingredients
• Known or suspected pregnancy

Important Safety Considerations

Endometrial Protection

Women with an intact uterus must receive concurrent progestin (daily or cyclically) to protect against endometrial stimulation and reduce endometrial cancer risk 3. Unopposed estrogen increases endometrial cancer risk 2.

Cardiovascular and Thromboembolic Risks

• Not recommended for primary or secondary prevention of cardiovascular disease 2
• Increases risk of stroke, deep venous thrombosis, and pulmonary embolism in an age-dependent manner 2, 4
• Smoking increases cardiovascular and venous thromboembolic risk when taking estrogen 2
• Transdermal estradiol may be preferred in women with hypertension, hypertriglyceridemia, or increased cholelithiasis risk 2

Other Risks

• Increased risk of probable dementia when used with progestin 4
• May increase ovarian epithelial tumors with use >10 years 2
• Increased gallbladder disease and urinary incontinence 4

Duration of Therapy

Current recommendations emphasize using Premarin for the shortest duration necessary consistent with treatment goals and individual risk assessment 2, 3.